Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo Limited ( (AU:PNV) ) has issued an announcement.
PolyNovo Limited announced record-breaking unaudited sales and revenue figures for March 2025, with monthly sales reaching A$11.9 million and total revenue hitting A$12.4 million. The company experienced significant growth across multiple regions, particularly in the United States and the United Kingdom, driven by increased account acquisition and the expanded use of their NovoSorb products. The strong financial performance and cash reserves position PolyNovo well to continue its strategic initiatives, including the completion of a new manufacturing facility and R&D innovation center.
More about Polynovo Limited
PolyNovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative products such as NovoSorb, which are used in various medical applications including burn treatment, plastics and reconstruction, limb salvage, orthopedic, and general surgery.
YTD Price Performance: -40.87%
Average Trading Volume: 4,404
Technical Sentiment Signal: Strong Buy
Current Market Cap: $436.4M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.